Shares of Harrow (HROW) have gained 5% over the past four weeks to close the last trading session at $47.20, but there could still be a solid upside left in the stock if short-term price targets of ...

Throughout the last three months, 4 analysts have evaluated Harrow HROW, offering a diverse set of opinions from bullish to bearish. The table below offers a condensed view of their recent ratings ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Students from Harrow International School hosted a music therapy programme for elderly individuals, collaborating with ...

Harrow focuses on ophthalmology products, including Iheezo, Vevye, and Triesence, but its clinical differentiation is debatable. HROW reported a record $48.9 million in Q2 revenue, a 46% year-over ...

Tech giant OpenAI has touted its artificial intelligence-powered transcription tool Whisper as having near “human level robustness and accuracy”. But Whisper has a major flaw: It is prone to making up ...

Harrow (HROW) shares soared 8.4% in the last trading session to close at $49.75. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to ...

The first AI-powered tools in the tech giant’s new Apple Intelligence range of features have been released to users in the United States.

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced the relaunch of TRIESENCE® ...

After last year's tragic 'Modern Warfare 3' campaign, 'Black Ops 6' has restored hope for 'Call of Duty' story fans, giving one of the best tales in franchise history.

NASHVILLE, Tenn., October 03, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced the relaunch of TRIESENCE® (triamcinolone acetonide injectable ...